Bioassay-guided isolation, identification of compounds from Origanum rotundifolium and investigation of their antiproliferative and antioxidant activities

Figures & data

Table 1. IC₅₀ values and tumour specificity rate for compounds.

	IC50 (μM)				Tumour specificity
Compounds	HeLa	HT29	C6	Vero	HeLa	HT29	C6
1	ND	ND	ND	ND	–	–	–
2	402.63	411.73	314.19	472.77	1.17	1.15	1.50
3	35.57	32.49	41.60	46.70	1.31	1.43	1.12
4	ND	ND	ND	ND	–	–	–
5	232.80	261.85	251.47	279.35	1.19	1.07	1.11
6	140.07	136.33	169.01	ND	–	–	–
Cisplatin	44.25	48.58	61.45	40.78	0.92	0.84	0.66

ND: not determined.

Figure 1. Isolated compounds from O. rotundifolium.

Figure 2. DPPH^• scavenging, ABTS^•+ scavenging and reducing power activities of isolated compounds and positive controls. (The same letters on the columns of DPPH and ABTS revealed that the differences are not significant statistically (p > 0.05). The different letters indicated that the differences are significant (p < 0.05).

Figure 3. The antiproliferative activity of compounds on C6, HeLa, HT29 and Vero cell lines. Cell proliferation was measured using a BrdU Cell Elisa Assay Kit. Percent inhibition was reported as mean values ± SEM of three independent assays (p < 0.05). Each experiment was repeated three times for each cell line.